|
HPTN 112 (39057) |
Improving HIV prevention among heterosexual men seeking STI services in Malawi: examining the benefits, acceptability, and associated costs of a systems-navigator-delivered integrated prevention package
|
Enrolling |
Integrated Strategy |
|
HPTN 111 (39062) |
Feasibility and Acceptability of a Barbershop Based HIV Prevention Initiative Among Heterosexual Men in Kalangala Islands, Uganda: A Cluster Randomized Trial
|
Closed to Accrual |
Integrated Strategy |
|
HVTN 143/HPTN 109 (39015) |
A phase 1- clinical trial to evaluate the safety, tolerability, pharmacokinetics and tolerability of combinations of monoclonal antibodies VRC01.23LS, PGT121.414.LS, and PGDM1400LS administered via intravenous infusion in adults without HIV
|
Withdrawn |
Antibody Mediated Prevention |
|
A5416/HVTN 806/HPTN 108 (39006) |
A Phase I, Randomized, Placebo-Controlled Study of the Safety, Antiviral & Immunomodulatory Activity of Broadly Neutralizing Antibodies 3BNC117-LS-J and 10-1074-LS-J in Combination in ART-treated Adults in sub-Saharan Africa Living with HIV during a Monitored Analytical Treatment Interruption
|
Enrolling |
Antibody Mediated Prevention |
|
DMID 19-0004/HPTN 107 |
A Phase II randomized, observer-blind, placebo-controlled study, to assess efficacy of meningococcal Group B vaccine rMenB+OMV NZ (Bexsero) in preventing gonococcal infection.
|
Enrolling |
|
|
HPTN 106 (39002) |
A Phase 2 Crossover Study of On Demand PrEP Formulations Comparing Rectal and Oral TFV-Based PrEP Evaluating Extended Safety, Acceptability, and PK/PD
|
Open to Accrual |
|
|
HVTN 140/HPTN 101 (154188) |
A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of PGDM1400LS alone and in combination with VRC07-523LS and PGT121.414.LS in healthy, HIV-uninfected adult participants
|
Closed to Follow Up |
Antibody Mediated Prevention |
|
CoVPN 5002 (38749) |
SARS-CoV-2 Prevalence Survey
|
Closed to Follow Up |
COVID-19 |
|
HPTN 083-02 (38645) |
Factors Influencing Adherence to Injectable PrEP and Retention in an Injectable PrEP Research Study
|
Closed to Follow Up |
PrEP |
|
HPTN 096 (38561) |
Getting to Zero Among Black MSM in the American South: Testing the Efficacy of an Integrated Intervention Strategy
|
Enrolling |
Integrated Strategy |
|
HVTN 804/HPTN 095 (38632) |
Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who received VRC01 or placebo and became HIV-infected during HVTN 704/HPTN 085
|
Closed to Accrual |
Other |
|
HPTN 094 (38715) |
INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit to Link Persons who Inject Drugs to Integrated Care and Prevention for Addiction, HIV, HCV and Primary Care.
|
Closed to Accrual |
Integrated Strategy |
|
HVTN 805/HPTN 093 (38691) |
Antiretroviral analytical treatment interruption (ATI) to assess immunologic and virologic responses in participants who initiated ART in early HIV infection after having received VRC01 or placebo in HVTN 703/HPTN 081
|
Closed to Follow Up |
Other |
|
HPTN 084-01 (38655) |
Ancillary Study: Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (LA CAB) for the Prevention of HIV among Adolescents
|
Closed to Follow Up |
PrEP |
|
HPTN 083-01 (38654) |
Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV among Adolescent Males – A sub-study of HPTN 083
|
Closed to Follow Up |
PrEP |
|
HVTN 136/HPTN 092 (38634) |
A phase 1 dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous infusion or via subcutaneous injections in healthy, HIV-uninfected adult participants.
|
Closed to Follow Up |
Antibody Mediated Prevention |
|
HPTN 091 (38695) |
Integrating HIV Prevention, Gender-Affirmative Medical Care, and Peer Health Navigation to Prevent HIV Acquisition and HIV Transmission for Transgender Women in the Americas: A Vanguard Feasibility and Acceptability Study
|
Closed to Accrual |
Integrated Strategy |
|
HVTN 130/HPTN 089 (38531) |
A phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion in healthy, HIV-uninfected adult participants
|
Concluded |
Antibody Mediated Prevention |
|
HVTN 127/HPTN 087 (38458) |
A multicenter, randomized, partially blinded phase 1 clinical trial to evaluate the safety and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses and routes to healthy, HIV-uninfected adults.
|
Concluded |
Antibody Mediated Prevention |
|
HPTN 084 (38070) |
A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women.
|
Closed to Accrual |
PrEP |
|
HVTN 704/HPTN 085 (30095) |
A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men.
|
Concluded |
Antibody Mediated Prevention |
|
HPTN 083 (20725) |
A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), for Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men
|
Closed to Accrual |
PrEP |
|
HPTN 082 (12068) |
Evaluation of Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study
|
Concluded |
PrEP |
|
HVTN 703/HPTN 081 (12045) |
A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa.
|
Concluded |
Antibody Mediated Prevention |
|
HPTN 078 (11995) |
Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex with Men (MSM) in the United States
|
Concluded |
Integrated Strategy |
|
HPTN 077 (11964) |
A Phase IIa Safety, Tolerability and Acceptability Study of an Investigational Injectable HIV Integrase Inhibitor, GSK1265744, for PrEP in HIV Uninfected Men and Women
|
Concluded |
PrEP |
|
HPTN 076 (11944) |
Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre Exposure Prophylaxis (PrEP)
|
Concluded |
PrEP |
|
HPTN 075 (11943) |
Feasibility of HIV Prevention Cohort Studies Among MSM in Sub-Saharan Africa
|
Concluded |
Behavioral |
|
HPTN 074 (11917) |
Integrated Treatment and Prevention for People Who Inject Drugs: A Vanguard study for a Network-based Randomized HIV Prevention Trial Comparing an Integrated Intervention Including Supported Antiretroviral Therapy to the Standard of Care
|
Concluded |
Treatment as Prevention |
|
HPTN 071 (11865) |
Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A cluster-randomized trial of the impact of a combination prevention package on population-level HIV incidence in Zambia and South Africa
|
Archived |
Treatment as Prevention |
|
HPTN 073 (11894) |
Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence among Black Men who have Sex with Men (BMSM) in Three U.S. Cities
|
Concluded |
PrEP |
|
HPTN 069 (11789) |
A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir disoproxil fumarate (MVC+TDF), or Tenofovir disoproxil fumarate + Emtricitabine (TDF+FTC) for Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission in At-Risk Men Who Have Sex with Men and in At-Risk Women
|
Concluded |
PrEP |
|
HPTN 068 (11710) |
Effects of cash transfer for the prevention of HIV in young South African women
|
Concluded |
Structural |
|
HPTN 067 (10852) |
A Phase II, Randomized, Open-Label, Pharmacokinetic and Behavioral Study of the Use of Intermittent Oral Emtricitabine/Tenofovir Disoproxil Fumarate
Pre-Exposure Prophylaxis (PrEP)
|
Concluded |
PrEP |
|
HPTN 066 (10851) |
Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate in Healthy Volunteers
|
Concluded |
Antiretroviral Therapy |
|
HPTN 065 (11685) |
TLC-Plus: A Study to Evaluate the Feasibility of an Enhanced Test, Link to Care, Plus Treat Approach for HIV Prevention in the United States
|
Concluded |
Integrated Strategy |
|
HPTN 064 (10705) |
The Women’s HIV SeroIncidence Study
|
Concluded |
Behavioral |
|
HPTN 063 (10668) |
Preparing for international prevention trials involving HIV-infected individuals in care settings
|
Concluded |
Behavioral |
|
HPTN 062 (10667) |
Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals with Acute and Early HIV-Infection
|
Concluded |
Behavioral |
|
HPTN 061 (10666) |
Feasibility of a community-level, multi-component intervention for Black MSM in preparation for a Phase IIB community-level randomized trial to test the efficacy of the intervention in reducing HIV incidence among Black MSM
|
Concluded |
Behavioral |
|
HPTN 039-01 (10067) |
Ancillary Study: Prospective Cohort Study of HPTN 039 Seroconverters: The Effect of HSV-2 Suppression on HIV-1 Viral Set Point
|
Concluded |
STD Control |
|
HPTN 059 (10145) |
Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel
|
Concluded |
Microbicides |
|
HPTN 058 (10144) |
A Phase III randomized controlled trial to evaluate the efficacy of drug treatment in prevention of HIV infection and death among opiate dependent injectors
|
Concluded |
Substance Use |
|
HPTN 057 (10143) |
A Phase I Open Label Trial of the Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in HIV-1 Infected Pregnant Women and their Infants
|
Concluded |
Perinatal |
|
HPTN 056 |
Characterization of Baseline Mucosal Indices of Injury and Inflammation in Men for Use in Rectal Microbicide Trials
|
Concluded |
Microbicides |
|
HPTN 055 |
HIV Prevention Preparedness Study
|
Concluded |
Microbicides |
|
HPTN 052 (10068) |
A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples
|
Concluded |
Treatment as Prevention |
|
HPTN 043 |
A Phase III Randomized Controlled Trial of Community Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand
|
Concluded |
Structural |
|
HPTN 037 (10125) |
A Phase III Randomized Study to Evaluate the Efficacy of a Network-oriented Peer Educator Intervention for the Prevention of HIV Transmission Among Injection Drug Users And Their Network Members
|
Concluded |
Substance Use |
|
HPTN 046 (10142) |
Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV Infected Women to Prevent Vertical HIV Transmission During Breastfeeding
|
Concluded |
Perinatal |
|
HPTN 049 |
Phase I Safety and Acceptability Study of the Vaginal Microbicide 6% Cellulose Sulfate Gel Among HIV-Infected Women
|
Concluded |
Microbicides |
|
HPTN 039 (10066) |
A Phase III, randomized, double-blind, placebo-controlled trial of acyclovir for the reduction of HIV acquisition among high risk HSV-2 seropositive, HIV-seronegative individuals
|
Concluded |
STD Control |
|
HPTN 035 (10065) |
Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO2000/5 Gel (P) for the Prevention of HIV Infection in Women
|
Concluded |
Microbicides |
|
HPTN 033 |
HIV Prevention Preparedness Study
|
Concluded |
Substance Use |
|
HPTN 050 |
Phase I Safety and Acceptability Study of the Vaginal Microbicide Agent PMPA Gel
|
Concluded |
Microbicides |
|
HPTN 036 |
HIV Prevalence, Incidence, and HSV-2 Prevalence Among High-Risk MSM in Perú
|
Concluded |
STD Control |
|
HPTN 034 (10199) |
HIV Incidence and Participant Retention Protocol, Pune, India
|
Concluded |
Other |
|
HPTN 047 |
A Phase I Safety and Acceptability Study of the Investigational Vaginal Microbicide PRO 2000/5 Gel (P)
|
Concluded |
Microbicides |
|
HPTN 032 |
Male Tolerance Study of BufferGel and PRO 2000/5 Gel (P)
|
Concluded |
Microbicides |
|
HPTN 027 (10141) |
A Phase I Study to Evaluate the Safety and Immunogenicity of ALVAC-HIV vCP1521 in Infants Born to HIV-1 Infected Women in Uganda
|
Concluded |
Perinatal |
|
HIVNET 016A |
Condom Promotion and Counseling Study
|
Concluded |
Microbicides |
|
HIVNET 015 |
EXPLORE: A Randomized Clinical Trial of the Efficacy of a Behavioral Intervention to Prevent Acquisition of HIV among Men who have Sex with Men (MSM)
|
Concluded |
Behavioral |
|
HIVNET 024 |
Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
|
Concluded |
Perinatal |
|
HIVNET 012 |
A Phase IIB Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates
|
Concluded |
Perinatal |